Morria Biopharmaceuticals Plc Announces Regulatory Approval To Commence Phase II Clinical Study Of MRX-4 In Allergic Rhinitis
Morria Biopharmaceuticals Plc, a
biopharmaceutical company focused on the development of novel
anti-inflammatory drugs, announced that it has obtained regulatory
approval from the South African Medicines Control Council (MCC) to initiate
a Phase II study of MRX-4 in 105 patients suffering from allergic rhinitis
(AR). The two-arm, randomized, multi-dose, double-blind, placebo-controlled
study includes a steroid comparator arm.
The study will evaluate the safety, tolerability, and preliminary
efficacy of intranasal MRX-4 in AR patients outside of allergy season as
compared with both placebo and an intranasal steroid. An experimental
multi-functional anti-inflammatory drug (MFAID), MRX-4 is a non-steroidal
potential treatment for AR that was shown to be safe and well tolerated in
a Phase I equivalent trial completed in Israel earlier this year.
"This study will provide valuable data regarding its potential in
allergic rhinitis, including efficacy, tolerability and pharmacokinetic
data," said Buy diflucan without prescription Dr. Yuval Cohen, president of Morria. "We are excited to be
taking this significant step toward testing a potentially safer, more
effective, and more affordable treatment option for the significant
commercial opportunity in the multi-billion dollar allergic rhinitis
market".
ABOUT ALLERGIC RHINITIS
Allergic rhinitis is a common condition that affects nearly 59 million
people in the United States (nearly 20 percent of the population) with a
market of close to $4 billion. Allergic rhinitis is characterized by
inflammation of the nasal membranes accompanied by symptoms that may
include sneezing, nasal congestion, nasal itching and rhinorrhea.
ABOUT MORRIA BIOPHARMACEUTICALS Plc
Morria Biopharmaceuticals Plc is a biopharmaceutical company focused on
the development of novel anti-inflammatory pharmaceuticals termed
multi-functional anti-inflammatory drugs (MFAIDs). This class of drugs
uniquely combines two promising approaches to preventing and reversing
inflammation: first, they control the phospholipase A2 (PLA2) enzyme
family, a known, but previously elusive anti-inflammatory drug target. At
the same time, they also protect cells and tissues against inflammatory
damage. Morria is determined to become a pivotal player in the $20 billion
anti-inflammatory drug market by developing and commercializing novel drugs
for acute pulmonary and gastro-intestinal inflammatory diseases. For more
information, please visit
This is not an invitation nor is it an offer to purchase or subscribe
for shares. This release is only intended for persons falling within the
exception set out in regulation 47 of the Financial Promotion order -
Persons in the business of disseminating information.
Morria Biopharmaceuticals Plc
Buy levitra without prescription | Buy generic ultram | Buy lasix without prescription